ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
P/E ratio for ViewRay, Inc. (VRAY)
P/E ratio as of 2022: -7.53
According to ViewRay, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.53. At the end of 2021 the company had a P/E ratio of -8.54.
P/E ratio history for ViewRay, Inc. from 2013 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -7.53 |
| 2021 | -8.54 |
| 2020 | -5.36 |
| 2019 | -3.50 |
| 2018 | -6.45 |
| 2017 | -7.50 |
| 2016 | -2.48 |
| 2015 | -2.13 |
| 2014 | 0.00 |
| 2013 | -0.15 |